Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 13

1.

Gene expression profile correlates with T-cell infiltration and relative survival in glioblastoma patients vaccinated with dendritic cell immunotherapy.

Prins RM, Soto H, Konkankit V, Odesa SK, Eskin A, Yong WH, Nelson SF, Liau LM.

Clin Cancer Res. 2011 Mar 15;17(6):1603-15. doi: 10.1158/1078-0432.CCR-10-2563. Epub 2010 Dec 6.

2.

Active dendritic cell immunotherapy for glioblastoma: Current status and challenges.

Polyzoidis S, Tuazon J, Brazil L, Beaney R, Al-Sarraj ST, Doey L, Logan J, Hurwitz V, Jarosz J, Bhangoo R, Gullan R, Mijovic A, Richardson M, Farzaneh F, Ashkan K.

Br J Neurosurg. 2015 Apr;29(2):197-205. doi: 10.3109/02688697.2014.994473. Epub 2014 Dec 26. Review.

PMID:
25541743
3.

Cellular-based immunotherapies for patients with glioblastoma multiforme.

Xu X, Stockhammer F, Schmitt M.

Clin Dev Immunol. 2012;2012:764213. doi: 10.1155/2012/764213. Epub 2012 Feb 28. Review.

4.

Perspectives for immunotherapy in glioblastoma treatment.

Finocchiaro G, Pellegatta S.

Curr Opin Oncol. 2014 Nov;26(6):608-14. doi: 10.1097/CCO.0000000000000135. Review.

PMID:
25210870
5.

Vaccine therapies for patients with glioblastoma.

Sayegh ET, Oh T, Fakurnejad S, Bloch O, Parsa AT.

J Neurooncol. 2014 Sep;119(3):531-46. doi: 10.1007/s11060-014-1502-6. Epub 2014 Aug 28. Review.

PMID:
25163836
6.
7.

Immunotherapy with dendritic cells loaded with glioblastoma stem cells: from preclinical to clinical studies.

Finocchiaro G, Pellegatta S.

Cancer Immunol Immunother. 2016 Jan;65(1):101-9. doi: 10.1007/s00262-015-1754-9. Epub 2015 Sep 16. Review.

PMID:
26377689
8.

An update on vaccine therapy and other immunotherapeutic approaches for glioblastoma.

Reardon DA, Wucherpfennig KW, Freeman G, Wu CJ, Chiocca EA, Wen PY, Curry WT Jr, Mitchell DA, Fecci PE, Sampson JH, Dranoff G.

Expert Rev Vaccines. 2013 Jun;12(6):597-615. doi: 10.1586/erv.13.41. Review.

9.

Biomarkers for glioma immunotherapy: the next generation.

Sims JS, Ung TH, Neira JA, Canoll P, Bruce JN.

J Neurooncol. 2015 Jul;123(3):359-72. doi: 10.1007/s11060-015-1746-9. Epub 2015 Feb 28. Review.

10.

Brain Tumor Immunotherapy: What have We Learned so Far?

Van Gool SW.

Front Oncol. 2015 Jun 17;5:98. doi: 10.3389/fonc.2015.00098. eCollection 2015. Review.

11.

Immunotherapy advances for glioblastoma.

Reardon DA, Freeman G, Wu C, Chiocca EA, Wucherpfennig KW, Wen PY, Fritsch EF, Curry WT Jr, Sampson JH, Dranoff G.

Neuro Oncol. 2014 Nov;16(11):1441-58. doi: 10.1093/neuonc/nou212. Epub 2014 Sep 4. Review.

12.

Dendritic cell vaccination for glioblastoma multiforme: review with focus on predictive factors for treatment response.

Dejaegher J, Van Gool S, De Vleeschouwer S.

Immunotargets Ther. 2014 Mar 13;3:55-66. doi: 10.2147/ITT.S40121. eCollection 2014. Review.

13.

[What's next in glioblastoma treatment: Tumor-targeted or immune-targeted therapies?].

Schernberg A, Marabelle A, Massard C, Armand JP, Dumont S, Deutsch E, Dhermain F.

Bull Cancer. 2016 May;103(5):484-98. doi: 10.1016/j.bulcan.2016.02.014. Epub 2016 Mar 28. Review. French.

PMID:
27032303
Items per page

Supplemental Content

Write to the Help Desk